Latest stock research reports with share price targets forecast, buy, hold, and sell recommendations along with upside. Search by company or broker name.
We remain positive on Granules' long-term growth and profitability, supported by new product launches across geographies, a focus on backward integration, and rising market share. Entry into the CDMO segment via the Senn acquisition, along with higher-margin oncology filings, is expected to strengthen financials. Moreover, resolution of regulatory issues at the Gagilapur facility could act as a key re-rating catalyst. Hence, we maintain an Accumulate rating on the...
The stage-3 asset ratio in the gold loan portfolio declined to 2.58% in Q1FY26 from 3.98% a year earlier, supported by customer-led repayments aided by rising gold prices and flexible repayment options....
Asian Markets are trading in the green on the back of the US Federal Reserve's 25 bps rate cut. Nikkei, Hang Seng and Shanghai are all trading positively by 0.88%, 0.11% and 0.11%, respectively.
About the stock: Siemens Energy India Ltd. (SEIL) is a leading player that provides technology and service in energy generation and transmission infrastructure. It has a comprehensive portfolio of products, solutions, and services designed to strengthen and expand grid infrastructure, addressing the growing demand while ensuring grid stability. Power transmission and power generation portfolio each contributed 50%...
Since inception the Company has delivered over 2.5 GW of module to domestic and international customers. It deploys range of technologies to fulfill diverse consumer needs, through a distribution network of 53 selling partners, including 23 resellers, 19 distributors and 11 channel partners.
The management maintains a long-term perspective on the business, aiming to navigate potential challenges and seize growth opportunities. We anticipate a steep revenue degrowth because of lower Revlimid sales in FY27. Focus will shift on the domestic formulations business with the anticipated launches of Semaglutide, which strengthens our case for...
Kolimigundla, debottlenecking of existing plants, and additional grinding capacities. We value TRCL at 15x FY27E EV/EBITDA (vs. 3-year average of ~14x), arriving at a target price of 1,270, and downgrade the rating to Accumulate....
Strong history of product launches: Abbott India has been steadily growing led by consistent launches of both - own and Novo Nordisk’s products (marketing). Abbott India has launched over 100 products in India in the last 12 years and we expect the pipeline to stay strong.
The opportunities for the entire Indian capital market ecosystem over the next decade, with a rising financialization trend but low penetration (demat penetration at 15% vs 60%+ in the US), continue to be immense (highlighted in our capital market thematic report).
Asian Markets are trading mixed after Wall Street declined as investors await the Fed meeting decision. Nikkei and Hang Seng are both trading positively by 0.18% and 0.69%, respectively, whereas Shanghai is trading negatively by 0.09%.
